Helius Medical to Challenge Medicare Reimbursement Decision for Neuromodulation Stimulator Mouthpiece

MT Newswires Live10-15

Helius Medical Technologies (HSDT) said Monday that it will challenge the Centers for Medicare & Medicaid Services' decision to finalize a $2,963.30 reimbursement for its portable neuromodulation stimulator mouthpiece, effective Jan. 1.

The new reimbursement determination corrects Medicare's initial decision of monthly rental payments, Helius added.

Medicare deferred its decision on the payment rate for its portable neuromodulation stimulator controller to the next payment cycle, according to the company.

Helius said it plans to continue advocating for appropriate pricing for both devices to increase patient access and drive revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment